Prevention And Management Of Chemotherapy-Induced Peripheral Neuropathy In Survivors Of Adult Cancers
Publication Date: July 14, 2020
Key Points
Key Points
- Chemotherapy-induced neuropathy (CIPN) is a serious clinical problem caused by a substantial number of cytotoxic drugs, including taxanes, platinums, vinca alkaloids, epothilones, eribulin, and bortezomib.
- No agents are recommended for the prevention of CIPN.
- Duloxetine is the only agent that has appropriate evidence to support its use, but the amount of benefit from duloxetine is limited.
- Therefore, prevention and minimizing risk are the primary objectives.
- Because patients with CIPN can have balance troubles and a higher chance of falling, it is reasonable to consider physical and/or occupational therapy approaches for patients with such CIPN-related disabilities.
Prevention
...eventio...
...hemotherapy-induced peripheral neuropathy...
...n 1.1Clinicians should assess the risks an...
...ndation 1.2Clinicians should NOT offer, and should...
...ndation 1.3Outside the context of...
....4Clinicians should NOT offer the following agents...
Treatment
Treatment
...t of chemotherapy-induced peripheral neuropathy...
...endation 2.1Clinicians should assess,...
...f chemotherapy-induced peripheral neuropathy...
...mmendation 3.1For cancer patients ex...
...mendation 3.2Outside the context of a...
Summary of Recommendations
...RecommendationsHaving trouble viewi...